ARCHIVES

Adverse data from cancer prevention trial makes Merck withdraw Vioxx from market. Researchers discuss implications for other cancer prevention trials.

This article is from The Cancer Letter archive.

Vol. 30 No. 39 | October 15, 2004

Download PDF Visit The Full Archive

Related Articles

Cancer Care Driven Toward: Triage” System, Puerto Rico Dean Tells AACI

July 21, 1989

Toxicology Program Seeks Comment On Substances.

March 23, 2001

Includes May issue of Business & Regulatory Report.

May 31, 2002

Clanton Resigns From NCI.

January 12, 2007

Raub Corrects Record on ALERT

April 20, 1984

Cancer Groups Endorse Pazdur For FDA Commissioner.

January 19, 2001